Oral metronomic cyclophosphamide in advanced ovarian cancer: long-lasting clinical response in an elderly frailty patient

被引：6

作者：

Villa, Michela ^{[1
]}

Attianese, Daniela ^{[1
]}

Petracchini, Massimo ^{[2
]}

Ferrero, Annamaria ^{[1
]}

机构：

[1] Univ Turin, Mauriziano Hosp, Acad Div Gynaecol & Obstet, Turin, Italy

[2] Univ Turin, Mauriziano Hosp, Radiol Dept, Turin, Italy

来源：

ANTI-CANCER DRUGS | 2019年 / 30卷 / 09期

关键词：

advanced ovarian cancer; elderly; frailty; metronomic chemotherapy; cyclophosphamide; GRADE SEROUS OVARIAN; FALLOPIAN-TUBE CANCERS; PRIMARY PERITONEAL; SALVAGE THERAPY; OLDER PATIENTS; CHEMOTHERAPY; WOMEN; OUTCOMES; TRIAL;

D O I：

10.1097/CAD.0000000000000815

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Elderly patients with ovarian cancer are an increasing population and many of them are frailty with an increased risk of postoperative complications, chemotherapy intolerance and mortality. Metronomic chemotherapy is the chronic administration of low, equally spaced, doses of antineoplastic drugs with therapeutic efficacy and low toxicity. Oral metronomic cyclophosphamide has gained increasing interest in recent years in the treatment of patients with recurrent ovarian cancer. We report the case of a 87-year-old and frailty woman with advanced ovarian cancer, not eligible for surgery or standard first-line intravenous chemotherapy. The patient has received oral metronomic cyclophosphamide with a long-lasting clinical response and improved performance status. Oral metronomic cyclophosphamide is a promising treatment for elderly and frailty advanced ovarian cancer patients and should be further investigated. Copyright (C) 2019 Wolters Kluwer Health, Inc. All rights reserved.

引用

页码：964 / 968

页数：5

共 25 条

[11] Ovarian Cancer in Elderly Patients Patterns of Care and Treatment Outcomes According to Age and Modified Frailty Index [J].

Ferrero, Annamaria ;

Fuso, Luca ;

Tripodi, Elisa ;

Tana, Roberta ;

Daniele, Alberto ;

Zanfagnin, Valentina ;

Perotto, Stefania ;

Gadducci, Angiolo .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (09) :1863-1871

[12] Measurement and validation of frailty as a predictor of outcomes in women undergoing major gynaecological surgery [J].

George, E. M. ;

Burke, W. M. ;

Hou, J. Y. ;

Tergas, A. I. ;

Chen, L. ;

Neugut, A. I. ;

Ananth, C. V. ;

Hershman, D. L. ;

Wright, J. D. .

BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2016, 123 (03) :455-461

[13] Delay in chemotherapy administration impacts survival in elderly patients with epithelial ovarian cancer [J].

Joseph, Naima ;

Clark, Rachel M. ;

Dizon, Don S. ;

Lee, Malinda S. ;

Goodman, Annekathryn ;

Boruta, David, Jr. ;

Schorge, John O. ;

del Carmen, Marcela G. ;

Growdon, Whitfield B. .

GYNECOLOGIC ONCOLOGY, 2015, 137 (03) :401-405

[14]

Gómez LJ, 2008, REV ESP ENFERM DIG, V100, P701

[15] Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer [J].

Kummar, Shivaani ;

Oza, Amit M. ;

Fleming, Gini F. ;

Sullivan, Daniel M. ;

Gandara, David R. ;

Naughton, Michael J. ;

Villalona-Calero, Miguel A. ;

Morgan, Robert J., Jr. ;

Szabo, Peter M. ;

Youn, Ahrim ;

Chen, Alice P. ;

Ji, Jiuping ;

Allen, Deborah E. ;

Lih, Chih-Jian ;

Mehaffey, Michele G. ;

Walsh, William D. ;

McGregor, Paul M., III ;

Steinberg, Seth M. ;

Williams, P. Mickey ;

Kinders, Robert J. ;

Conley, Barbara A. ;

Simon, Richard M. ;

Doroshow, James H. .

CLINICAL CANCER RESEARCH, 2015, 21 (07) :1574-1582

[16] Estimating the risk of chemotherapy toxicity in older patients with cancer: The role of the Vulnerable Elders Survey-13 (VES-13) [J].

Luciani, Andrea ;

Biganzoli, Laura ;

Colloca, Giuseppe ;

Falci, Cristina ;

Castagneto, Bruno ;

Floriani, Irene ;

Battisti, Nicolo ;

Dottorini, Lorenzo ;

Ferrari, Daris ;

Fiduccia, Pasquale ;

Zafarana, Elena ;

Del Monte, Francesca ;

Galli, Francesca ;

Monfardini, Silvio ;

Foa, Paolo .

JOURNAL OF GERIATRIC ONCOLOGY, 2015, 6 (04) :272-279

[17] Detecting Disabilities in Older Patients With Cancer: Comparison Between Comprehensive Geriatric Assessment and Vulnerable Elders Survey-13 [J].

Luciani, Andrea ;

Ascione, Gilda ;

Bertuzzi, Cecilia ;

Marussi, Desire ;

Codeca, Carla ;

Di Maria, Giuseppe ;

Caldiera, Sarah Elisabetta ;

Floriani, Irene ;

Zonato, Sabrina ;

Ferrari, Daris ;

Foa, Paolo .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) :2046-2050

[18] Low dose cyclophosphamide: Mechanisms of T cell modulation [J].

Madondo, Mutsa Tatenda ;

Quinn, Michael ;

Plebanski, Magdalena .

CANCER TREATMENT REVIEWS, 2016, 42 :3-9

[19] Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results [J].

Piccart, MJ ;

Bertelsen, K ;

James, K ;

Cassidy, J ;

Mangioni, C ;

Simonsen, E ;

Stuart, G ;

Kaye, S ;

Vergote, I ;

Blom, R ;

Grimshaw, R ;

Atkinson, RJ ;

Swenerton, KD ;

Trope, C ;

Nardi, M ;

Kaern, J ;

Tumolo, S ;

Timmers, P ;

Roy, JA ;

Lhoas, F ;

Lindvall, B ;

Bacon, M ;

Birt, A ;

Andersen, JE ;

Zee, B ;

Paul, J ;

Baron, B ;

Pecorelli, S .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (09) :699-708

[20] Evidence of extended (>7 years) activity of bevacizumab and metronomic cyclophosphamide in a patient with platinum-resistant low-grade serous ovarian carcinoma [J].

Rose, Peter G. ;

Roma, Andres .

ANTI-CANCER DRUGS, 2013, 24 (09) :986-988

← 1 2 3 →